AbCellera Biologics Inc reported third quarter 2026 revenue of $10.6 million and an EPS loss of $0.13, both exceeding analyst expectations. Results were characterized by a transition toward internal drug discovery, marked by positive clinical data for lead asset ABCL635 and a strengthened balance sheet following a $200 million capital raise. While internal progress is accelerating, the company's partner-led pipeline contracted as it focuses resources on high-conviction internal candidates, though it achieved positive year-to-date operating cash flow of $19.3 million.
Key Highlights
- AbCellera reported third quarter revenue of $10.6 million, surpassing the $8.41 million consensus estimate primarily through $10.5 million in research fee contributions.
- Lead internal asset ABCL635 demonstrated a 37% complete resolution of vasomotor symptoms at four weeks, significantly outperforming the 2% resolution observed in the placebo group.
- Total available liquidity reached $890 million, bolstered by a $200 million common share offering and approximately $100 million in available non-dilutive government funding.
- The company announced it will not develop ABCL575 beyond Phase 1 despite meeting all endpoints, signaling a strategic focus on the menopausal and oncology segments of its pipeline.